Nicorette, Axid switches scheduled for Sept. 28 NDAC meeting.
This article was originally published in The Tan Sheet
Executive Summary
NICORETTE AND AXID OTC SWITCHES SCHEDULED FOR NDAC REVIEW on Sept. 28. In the morning and early afternoon, FDA's Nonprescription Drug and Drug Abuse Advisory Committees will discuss SmithKline Beecham's Rx-to-OTC switch application for Nicorette nicotine chewing gum 2 mg and 4 mg (NDAs 20-066 and 18-612).
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning